Report recommends ways to improve response to toxic inhalation disasters

April 21, 2017

April 21, 2017--Better medical responses to the accidental or intentional release of inhaled toxic chemicals are being developed, but the field faces considerable challenges, according to a new report by an international panel of experts.

The report, "Chemical Inhalation Disasters: Biology of Lung Injury, Development of Novel Therapeutics, and Medical Preparedness," has been published online in the Annals of the American Thoracic Society.

The 16-member panel's findings and recommendations grew out of a workshop sponsored by the American Thoracic Society (ATS) and the National Institutes of Health's (NIH) Countermeasures Against Chemical Threats (CounterACT) Program.

"The modern global geopolitical climate and recent events have shown us that chemical threats are real," said Eleanor M. Summerhill, MD, lead author of the report and a pulmonary and critical care physician at Lahey Hospital and Medical Center, in Burlington, Mass. "Current standard medical therapies have often been extrapolated from treatments for other forms of lung injury based upon scant supportive data."

She added that the aims of the workshop were to discuss innovative investigative approaches to furthering understanding of the pathophysiologic mechanisms of inhalation lung injuries, highlight promising new therapeutic targets and novel medical countermeasures and identify future directions in the development, manufacture and distribution of specific and effective medical countermeasures.

The panelists wrote that hurdles to ongoing research in the field "include the relative rarity and unpredictability of toxic inhalationl events" and "inherent ethical constraints restricting research and testing in humans."

Given these obstacles, the panel called for: According to the panel, "novel therapies require up to 10 years or more to achieve FDA approval, with recent cost estimates in excess of $800 million." Given the irregular occurrence of accidental and intentional chemical inhalation disasters, the panel added that pharmaceutical companies may find it prohibitively expensive to pursue FDA approval of medicines for use in inhalation disasters, even if the medicine are already approved in the treatment of other lung problems.

The report reviews current treatments and research related to chlorine, bromine, phosgene, cyanide, sulfur mustard and respirable nerve agents, including sarin. It also highlights epidemiologic findings from the 2001 terrorist attack on the World Trade Center and the massive 2005 chlorine gas leak caused by a train accident in Graniteville, South Carolina.

"Because inhalational disasters and chemical threats remain real, a continued awareness of public need is necessary," the panelists wrote. "In the U.S., even with the combined resources of the NIH, Health and Human Services' Biomedical Advance Research and Development Authority (BARDA), and the Department of Defense, the costs of countermeasure development and FDA approval are challenging."

The panelists added that a robust global response to the danger of chemical inhalations "requires tenacity and commitment to negotiate collaborations, funding sources, intellectual property and other concerns."
Share via Twitter

"Report highlights medical challenge of responding to accidental or intentional release of inhaled toxic chemicals."

Follow Us

ATS - @atscommunity

AJRCCM - @AnnalsATSEditor

About the Annals of the American Thoracic Society (AnnalsATS)

The AnnalsATS is a peer-reviewed journal published by the American Thoracic Society. The Journal delivers up-to-date and authoritative coverage of adult and pediatric pulmonary and respiratory sleep medicine and adult critical care. The scope of the Journal encompasses content that is applicable to clinical practice, the formative and continuing education of clinical specialists and the advancement of public health. Editor: David Lederer, M.D., M.S., associate professor of medicine and epidemiology and associate division chief for clinical and translational research at Columbia University.

About the American Thoracic Society

Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society's 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.

The ATS will hold its 2017 International Conference, May 19-24, in Washington, DC, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.

American Thoracic Society

Related Lung Injury Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

Study shows heating in vaping device as cause for lung injury
Early results of an experimental vaping study have shown significant lung injury from E-cigarette (eC) devices with nickel-chromium alloy heating elements.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Perceived harm of e-cigarettes vs cigarettes after outbreak of vaping-associated lung injury
This survey study looked at perceptions of the harms of electronic cigarettes compared to regular cigarettes among current smokers in England before and after the US outbreak of vaping-associated lung injury in 2019.

Characteristics of adolescents, adults with e-cigarette or vaping product use-associated lung injury
Following an outbreak of electronic cigarette or vaping product use-associated lung injury (EVALI) linked to hospitalizations and deaths, this  study used data reported to the Centers for Disease Control and Prevention to compare demographic and clinical characteristics, along with substance use behaviors, between adolescents and adults with EVALI.

Lung injury in COVID-19 is not high altitude pulmonary edema
A group of researchers with experience in treating high altitude pulmonary edema (HAPE) have written to correct the misconception in medical social media forums and elsewhere that the lung injury seen in COVID-19 is not like typical acute respiratory distress syndrome (ARDS) and is instead like HAPE.

Types of vaping products used by hospitalized patients with severe lung injury
This report describes the kinds of vaping products used by and the clinical characteristics of patients hospitalized in California last year with e-cigarette or vaping-associated lung injury.

Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease
The authors determined that tumor-derived ANGPTL2 stimulates lung epithelial cells, which is essential for primary tumor-induced neutrophil recruitment in lung and subsequent pre-metastatic niche formation.

Read More: Lung Injury News and Lung Injury Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to